Back to Journals » International Journal of Nephrology and Renovascular Disease » Volume 13

Practical Strategy for Treating Chronic Kidney Disease (CKD)-Associated with Hypertension

Authors Nagata D, Hishida E, Masuda T

Received 25 April 2020

Accepted for publication 11 June 2020

Published 7 July 2020 Volume 2020:13 Pages 171—178

DOI https://doi.org/10.2147/IJNRD.S259931

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Professor Pravin Singhal


Daisuke Nagata, Erika Hishida, Takahiro Masuda

Division of Nephrology, Department of Internal Medicine, Jichi Medical University, Tochigi, Japan

Correspondence: Daisuke Nagata Tel +81 285 58 7346
Fax +81 285 44 4869
Email nagatad@jichi.ac.jp

Abstract: When renal function declines, blood pressure rises, which in turn causes the kidneys to deteriorate. In order to stop this vicious cycle, it is necessary to lower the blood pressure to a “moderate” level in patients who have chronic kidney disease (CKD)-associated hypertension. Such optimization is problematic, since tight control of blood pressure might worsen the prognosis in elderly patients with CKD, especially those with advanced arteriosclerosis. Although renin-angiotensin system (RAS) inhibitors, angiotensinogen converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) are first-line drugs for hypertensive patients with diabetes, they should be used with caution depending on the patients’ conditions. Recently, there has been a focus on the preventive effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors, anti-diabetic drugs that have been shown to have an impact, on heart and kidney complications. SGLT2 inhibitors increase the amount of sodium chloride delivered to the macular densa of the distal tubules and correct glomerular hyperfiltration by contraction of afferent arterioles via the tubule-glomerular feedback system. It might be one of the reasons why SGLT2 inhibitors show the renal- and cardio-protective effects; however, the mechanism behind their function remains to be elucidated.

Keywords: chronic kidney disease, CKD, hypertension, atherosclerosis, intensive blood pressure control, renin-angiotensin system inhibitors, RAS inhibitors, sodium-glucose cotransporter 2 inhibitors, SGLT2 inhibitors

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]